OTC-Mediated Ornithine Accumulation Links Realgar CNS Toxicity

Study Background and Research Question

Realgar, a mineral-based traditional Chinese medicine containing arsenic, has been widely used for centuries in various clinical settings. Despite its therapeutic applications, concerns about its central nervous system (CNS) toxicity have grown, particularly in light of chronic arsenic exposure through realgar-containing patent medicines. While astrocytes—the primary glial cells maintaining CNS energy metabolism—are known targets of arsenic, the molecular link between realgar-induced hepatic dysfunction and brain injury remained unclear. The reference study (Ping Ye et al., 2025) sought to elucidate how hepatic enzymes and urea cycle intermediates orchestrate arsenic neurotoxicity through the liver–brain axis.

Key Innovation from the Reference Study

The study introduces a new paradigm in neurotoxicology by demonstrating that hepatic dysfunction—specifically, inhibition of ornithine transcarbamylase (OTC)—leads to systemic and cerebral accumulation of L-Ornithine ((S)-2,5-diaminopentanoic acid), which in turn regulates the transcription factor ZBTB7A in astrocytes. This regulatory axis suppresses glycolytic gene expression, resulting in impaired astrocyte energy metabolism and increased neuronal vulnerability to arsenic toxicity. The mechanistic insight provided by linking the urea cycle intermediate, ornithine, to CNS metabolic homeostasis represents a significant advancement in understanding organ crosstalk in toxicological processes (Ping Ye et al., 2025).

Methods and Experimental Design Insights

The research leveraged both in vivo animal models and in vitro cell-based systems to dissect the molecular events underpinning realgar’s CNS toxicity. Key experimental approaches included:

• Conditional intervention mouse models with targeted gene knockdown (Zbtb7aGfABC1D KD), OTC overexpression (OtcTBG OE), and pharmacological intervention (chrysophanol) were established and subjected to realgar exposure.
• Single-cell transcriptome sequencing and metabolomic profiling were employed to characterize cellular responses and metabolic shifts in the liver and frontal lobe.
• C8-D1A astrocyte cell lines were transfected with si-Zbtb7a and exposed to inorganic arsenic (iAs3+) and exogenous L-Ornithine.
• Neurobehavioral assessments, molecular biology assays, and histopathological analyses were used to quantify CNS damage and functional outcomes.
• Molecular docking was performed to evaluate the binding affinity between ornithine and ZBTB7A.

This integrative design enabled the authors to map the molecular chain of events from hepatic enzyme inhibition to CNS injury.

Protocol Parameters

• metabolic enzyme assay | 17.3 mg/mL (L-Ornithine in water) | astrocyte metabolism studies | matches solubility required for aqueous-based enzyme assays | product_spec
• cell exposure concentration | context-specific (e.g., 100–500 μM L-Ornithine) | in vitro astrocyte experiments | matches published ranges for metabolic modulation without inducing cytotoxicity | workflow_recommendation
• storage condition | –20°C (L-Ornithine solid) | long-term reagent stability | prevents compound degradation; solution storage not recommended | product_spec
• animal model dosage | realgar and ornithine dosing per body weight, titrated by toxicity endpoints | CNS-liver axis exploration | aligns with in vivo toxicology best practices | paper

Core Findings and Why They Matter

The study provides strong evidence that arsenic from realgar crosses the blood–brain barrier and accumulates in the frontal lobe, where it triggers ZBTB7A-mediated repression of glycolytic genes in astrocytes (Aldoa, Ldha, Pgam1). This results in a reduction of lactate production, essential for neuronal energy supply, and leads to energy deficits, apoptosis, and oxidative damage in the brain (Ping Ye et al., 2025). Behaviorally, this manifests as impaired learning and memory, reduced exploratory activity, and heightened anxiety-like behavior in exposed animals. A critical mechanistic insight is the identification of hepatic OTC inhibition as a proximal event: realgar suppresses OTC activity, leading to elevated systemic and cerebral L-Ornithine levels. Molecular docking and transcriptomic analysis indicate that ornithine interacts with ZBTB7A, amplifying its repression of glycolytic genes and exacerbating CNS toxicity. This positions ornithine not just as a biomarker but as an active metabolic modulator linking liver dysfunction to brain injury (Ping Ye et al., 2025). Moreover, the study shows that chrysophanol can mitigate both hepatic and CNS toxicity by protecting glycolytic function and normalizing the ornithine cycle, highlighting potential therapeutic avenues.

Comparison with Existing Internal Articles

The mechanistic connections described in this study reinforce and extend themes discussed in several recent internal resources. For example, "L-Ornithine in CNS Toxicity: Bridging Urea Cycle and Brain Health" addresses the role of L-Ornithine as a urea cycle intermediate in linking hepatic ammonia detoxification with CNS integrity, but the reference study provides new evidence for direct transcriptional regulation via ZBTB7A. Similarly, "L-Ornithine: Advanced Insights into Urea Cycle Disruption" discusses how disruption of the ornithine cycle impacts CNS function, yet the present article offers specific molecular actors and pathways validated by multi-modal experimentation. Furthermore, "L-Ornithine as a Translational Lever" emphasizes the utility of high-purity L-Ornithine in experimental workflows, directly supporting the kind of metabolic enzyme assays and astrocyte culture systems utilized in the reference study. Collectively, these articles provide a broader context and practical guidance, while the new research offers unprecedented molecular resolution and in vivo validation.

Limitations and Transferability

While the study presents compelling evidence for the OTC-ornithine-ZBTB7A axis in realgar-induced neurotoxicity, certain limitations should be acknowledged. First, the findings are primarily derived from murine models and immortalized astrocyte lines, which may not fully recapitulate human physiology. Second, although molecular docking suggests a direct ornithine–ZBTB7A interaction, further structural and functional validation would strengthen this claim. Third, the clinical relevance of realgar exposure levels and the translatability to human risk assessment remain areas for future investigation (Ping Ye et al., 2025). Nevertheless, the integrative methodology and focus on a urea cycle intermediate as a mediator of CNS effects suggest that these results are highly relevant to researchers exploring metabolic enzyme assays, neurotoxicology, and the broader field of liver–brain axis research. Application to other toxins or metabolic pathologies should be approached with caution pending further validation.

Research Support Resources

For laboratory studies aiming to replicate or extend these findings, high-purity L-Ornithine ((S)-2,5-diaminopentanoic acid) is essential for modeling urea cycle disruption and evaluating the ammonia detoxification pathway. Researchers can source validated L-Ornithine (SKU B8919) for such applications from APExBIO, ensuring rigorous control over assay inputs and facilitating reproducibility in metabolic and neurotoxicology workflows (source: product_spec). For optimal results, attention to solubility and storage parameters is advised, as outlined above. This resource supports advanced amino acid metabolism research, particularly for studies at the intersection of hepatic and CNS health.